What Portec-3?
The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.
What does Portec stand for?
The international randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women with High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of adjuvant chemotherapy in combination with EBRT (chemoradiotherapy (CTRT)) versus EBRT alone (radiotherapy (RT)) in patients with high-risk EC [2].
What is portec trial?
The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis.
What is high-risk endometrial cancer?
High-risk endometrial cancer is a heterogenous subgroup with a more aggressive clinical course. It includes those with one or more defined clinical or pathological risk factors for recurrence and mortality. Surgery remains the primary treatment modality for women with resectable endometrial cancer.
How is uterine cancer stage determined?
Endometrial cancer stages range from stage I (1) through IV (4). As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread to other parts of the body. And within a stage, an earlier letter means a lower stage.
What is uterine cancer stage3?
Cancer has spread beyond the uterus and cervix, but has not spread beyond the pelvis. Stage III is divided into stages IIIA, IIIB, and IIIC, based on how far the cancer has spread within the pelvis.
How long can you live with stage 3 endometrial cancer?
Staging and Survival Rate Survival for stage 3 or 4 endometrial cancer depends on how successful surgery has been and how much tumour had to be left behind after surgery. FIGO reports the five-year survival rate of distant (late-stage) endometrial cancer is 17%.
What is portec-3?
Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup.
How many consenting patients were there in the portec-3 trial?
FFPE tissue was collected from 423 consenting patients from 5 of the 6 clinical trial groups participating in the PORTEC-3 clinical trial.7The design and results of the PORTEC-3 trial have been reported previously7and are further described in the Data Supplement.
What is the role of radiotherapy in the portec-3 study?
In PORTEC-3 study, the patients with high-risk disease were randomly assigned to receive pelvic radiotherapy alone or the combination of radiotherapy with two cycles of concurrent cisplatin followed by four cycles of adjuvant paclitaxel/carboplatin. The study co-primary endpoints were OS and FFS.